1. Home
  2. MDIA vs IMMP Comparison

MDIA vs IMMP Comparison

Compare MDIA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

N/A

Current Price

$0.83

Market Cap

50.0M

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.62

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDIA
IMMP
Founded
2019
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.0M
58.2M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
MDIA
IMMP
Price
$0.83
$0.62
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
30.4K
22.9M
Earning Date
05-19-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$133,336,000.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.52
N/A
52 Week Low
$0.54
$0.29
52 Week High
$1.60
$3.53

Technical Indicators

Market Signals
Indicator
MDIA
IMMP
Relative Strength Index (RSI) 61.31 40.17
Support Level $0.57 $0.29
Resistance Level $0.87 $1.89
Average True Range (ATR) 0.07 0.08
MACD 0.01 0.12
Stochastic Oscillator 81.44 42.48

Price Performance

Historical Comparison
MDIA
IMMP

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: